选择性眼动脉灌注化疗治疗晚期眼内视网膜母细胞瘤：辛辛那提儿童医院医疗中心的早期经验。
Selective Ophthalmic Artery Infusion Chemotherapy for Advanced Intraocular Retinoblastoma: CCHMC Early Experience.
作者信息
Michaels Samantha T, Abruzzo Todd A, Augsburger James J, Corrêa Zélia M, Lane Adam, Geller James I
机构信息
*Division of Oncology †Department of Radiology, Cincinnati Children's Hospital Medical Center ‡Department of Ophthalmology, University of Cincinnati, Cincinnati, OH.
出版信息
J Pediatr Hematol Oncol. 2016 Jan;38(1):65-9. doi: 10.1097/MPH.0000000000000471.
Selective ophthalmic artery infusion chemotherapy (SOAIC) is increasingly used to treat retinoblastoma. We report the toxicities and outcome of 19 eyes in 17 patients with retinoblastoma receiving SOAIC treatment between 2008 and 2013. From the 87 treatments, mild local reactions were common. Myelosuppression was more common after triple-agent SOAIC (melphalan, carboplatin, and topotecan) than single-agent melphalan. Ocular salvage was achieved in 11 of 19 eyes and associated with triple-agent therapy. SOAIC is a effective therapy for some retinoblastoma with manageable toxicity; however, systemic toxicity increases with increasing therapeutic intensity of SOAIC.
选择性眼动脉灌注化疗（SOAIC）越来越多地用于治疗视网膜母细胞瘤。我们报告了2008年至2013年间17例接受SOAIC治疗的视网膜母细胞瘤患者的19只眼的毒性反应和治疗结果。在87次治疗中，轻度局部反应很常见。三联药物SOAIC（美法仑、卡铂和拓扑替康）治疗后骨髓抑制比单药美法仑治疗更常见。19只眼中有11只实现了眼球挽救，且与三联药物治疗相关。SOAIC是治疗某些视网膜母细胞瘤的有效疗法，毒性可控；然而，随着SOAIC治疗强度的增加，全身毒性也会增加。
Zotero 插件